CA2742961C - Anti-tgf-beta receptor ii antibodies - Google Patents

Anti-tgf-beta receptor ii antibodies Download PDF

Info

Publication number
CA2742961C
CA2742961C CA2742961A CA2742961A CA2742961C CA 2742961 C CA2742961 C CA 2742961C CA 2742961 A CA2742961 A CA 2742961A CA 2742961 A CA2742961 A CA 2742961A CA 2742961 C CA2742961 C CA 2742961C
Authority
CA
Canada
Prior art keywords
seq
antibody
human
tgfprii
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2742961A
Other languages
English (en)
French (fr)
Other versions
CA2742961A1 (en
Inventor
Yan Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone LLC filed Critical ImClone LLC
Publication of CA2742961A1 publication Critical patent/CA2742961A1/en
Application granted granted Critical
Publication of CA2742961C publication Critical patent/CA2742961C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2742961A 2008-11-07 2009-10-29 Anti-tgf-beta receptor ii antibodies Expired - Fee Related CA2742961C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19869708P 2008-11-07 2008-11-07
US61/198,697 2008-11-07
US17036909P 2009-04-17 2009-04-17
US61/170,369 2009-04-17
PCT/US2009/062450 WO2010053814A1 (en) 2008-11-07 2009-10-29 Anti-tgf-beta receptor ii antibodies

Publications (2)

Publication Number Publication Date
CA2742961A1 CA2742961A1 (en) 2010-05-14
CA2742961C true CA2742961C (en) 2016-08-30

Family

ID=41508691

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2742961A Expired - Fee Related CA2742961C (en) 2008-11-07 2009-10-29 Anti-tgf-beta receptor ii antibodies

Country Status (19)

Country Link
US (2) US8147834B2 (enExample)
EP (1) EP2356152A1 (enExample)
JP (1) JP5667067B2 (enExample)
KR (1) KR101283856B1 (enExample)
CN (1) CN102209727B (enExample)
AR (1) AR073909A1 (enExample)
AU (1) AU2009311375B2 (enExample)
BR (1) BRPI0921263A2 (enExample)
CA (1) CA2742961C (enExample)
EA (1) EA025169B1 (enExample)
IL (1) IL211842A (enExample)
JO (1) JO3096B1 (enExample)
MX (1) MX2011004871A (enExample)
NZ (1) NZ591943A (enExample)
PA (1) PA8846101A1 (enExample)
SG (1) SG10201401280TA (enExample)
TW (1) TWI384998B (enExample)
WO (1) WO2010053814A1 (enExample)
ZA (1) ZA201103178B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013007936A (es) * 2011-01-06 2013-08-09 Glaxo Group Ltd Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta.
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
KR20170074243A (ko) 2014-10-31 2017-06-29 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 변형된 t 세포의 생성 방법 및 조성물
AU2015380397B2 (en) 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
EP4169942A1 (en) 2016-03-11 2023-04-26 Scholar Rock, Inc. Tgfbeta1-binding immunoglobulins and use thereof
AU2017268469C1 (en) * 2016-05-20 2025-01-02 President And Fellows Of Harvard College Gene therapy methods for age-related diseases and conditions
AR109770A1 (es) * 2016-10-18 2019-01-23 Lilly Co Eli ANTICUERPOS DEL RECEPTOR II DE TGF-b
US20180207267A1 (en) * 2017-01-06 2018-07-26 Scholar Rock, Inc. Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
CN106884005A (zh) * 2017-01-19 2017-06-23 樊克兴 一种结直肠癌抗原特异性t细胞的制备方法
CN111601616A (zh) 2017-10-24 2020-08-28 美真达治疗公司 用于耗尽cd117+细胞的组合物和方法
JP7280254B2 (ja) 2017-10-24 2023-05-23 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ１１７＋細胞を減少させるための組成物及び方法
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
CN107973853B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备Smad2蛋白特异性抗体的方法及其应用
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
PH12022551527A1 (en) * 2019-12-24 2024-01-29 Merus Nv Tgf-beta-rii binding proteins
KR102314157B1 (ko) * 2020-01-10 2021-10-19 주식회사 뉴클릭스바이오 TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
JP2025512025A (ja) * 2022-04-15 2025-04-16 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 抗ｃｄ４０抗体及びその使用
CN116178567B (zh) * 2022-10-28 2025-01-28 四川大学华西医院 一种靶向TGFβRII的嵌合抗原受体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JP4124815B2 (ja) * 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
JP2004121001A (ja) * 2002-08-07 2004-04-22 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対する高親和性モノクローナル抗体
US20090186076A1 (en) * 2006-02-01 2009-07-23 Kazunori Kataoka Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent

Also Published As

Publication number Publication date
KR101283856B1 (ko) 2013-07-15
MX2011004871A (es) 2011-07-13
ZA201103178B (en) 2012-10-31
JO3096B1 (ar) 2017-03-15
WO2010053814A1 (en) 2010-05-14
CA2742961A1 (en) 2010-05-14
KR20110067155A (ko) 2011-06-21
NZ591943A (en) 2012-11-30
IL211842A (en) 2016-09-29
AU2009311375A1 (en) 2010-05-14
US20100119516A1 (en) 2010-05-13
CN102209727B (zh) 2014-07-30
JP5667067B2 (ja) 2015-02-12
US8147834B2 (en) 2012-04-03
EA201170659A1 (ru) 2011-10-31
EA025169B1 (ru) 2016-11-30
TW201026326A (en) 2010-07-16
IL211842A0 (en) 2011-06-30
BRPI0921263A2 (pt) 2015-08-04
TWI384998B (zh) 2013-02-11
AU2009311375B2 (en) 2014-07-31
CN102209727A (zh) 2011-10-05
JP2012508170A (ja) 2012-04-05
SG10201401280TA (en) 2014-05-29
AR073909A1 (es) 2010-12-09
US20120177666A1 (en) 2012-07-12
EP2356152A1 (en) 2011-08-17
PA8846101A1 (es) 2010-06-28

Similar Documents

Publication Publication Date Title
CA2742961C (en) Anti-tgf-beta receptor ii antibodies
JP2012508170A5 (enExample)
US20240228635A9 (en) Ccr8 antibody and application thereof
KR102688969B1 (ko) Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
JP6140777B2 (ja) ヒトｉｌ−６受容体に対する高親和性抗体
EP2694552B1 (en) Novel egfr binding proteins
EP1819358B1 (en) Antibodies against vascular endothelial growth factor receptor-1
CN105829345B (zh) 结合egfr和met的多功能抗体
JP2010504331A (ja) グルカゴン受容体抗体に関する組成物および方法
US11008387B2 (en) Antibody inhibiting binding of VEGF to NRP1
WO2005120557A2 (en) Inhibition of macrophage-stimulating protein receptor (ron)
KR20230159823A (ko) Cd112r에 대한 항체 및 이의 용도
EP3777889A1 (en) Use of probdnf regulator in b cell-related diseases
CA2762446A1 (en) Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis
KR20250114286A (ko) 개과 악성종양에 대한 면역제
CN115515637A (zh) 使用il-20拮抗剂和免疫检查点抑制剂的混合式治疗

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20191029